Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Symptom Control With or Without Docetaxel in Treating Patients With Relapsed Esophageal Cancer or Stomach Cancer

This study has been completed.
Information provided by:
National Cancer Institute (NCI) Identifier:
First received: September 16, 2009
Last updated: August 6, 2013
Last verified: September 2009

RATIONALE: Analgesics, antiemetics, steroids, and radiation therapy are effective in helping to control symptoms caused by cancer. It is not yet known whether these treatments are more effective when given with or without docetaxel in treating patients with relapsed esophageal cancer or stomach cancer.

PURPOSE: This randomized phase II trial is studying symptom control given together with docetaxel to see how well it works compared with symptom control given without docetaxel in treating patients with relapsed esophageal cancer or stomach cancer.

Condition Intervention Phase
Adenocarcinoma of the Gastroesophageal Junction
Esophageal Cancer
Gastric Cancer
Nausea and Vomiting
Drug: docetaxel
Drug: steroid therapy
Other: questionnaire administration
Procedure: nausea and vomiting therapy
Procedure: pain therapy
Procedure: quality-of-life assessment
Procedure: standard follow-up care
Radiation: radiation therapy
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Masking: Open Label
Primary Purpose: Treatment
Official Title: Randomised Phase III Study of Docetaxel vs Active Symptom Control in Patients With Relapsed Oesophago-gastric Adenocarcinoma

Resource links provided by NLM:

Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • Overall survival

Secondary Outcome Measures:
  • Time to documented progression (arm I)
  • Response rate (arm I)
  • Toxicity (arm I)
  • Quality of life as assessed by EORTC QLQ-C30 and -STO22
  • Health economic evaluation as assessed by EQ-5D

Estimated Enrollment: 320
Study Start Date: April 2008
Study Completion Date: October 2010
Primary Completion Date: April 2010 (Final data collection date for primary outcome measure)
Detailed Description:



  • To compare overall survival of patients with relapsed adenocarcinoma of the esophagus or stomach after treatment with docetaxel and active symptom control vs active symptom control alone.


  • To determine the time to documented progression in patients treated with docetaxel.
  • To assess response rates to docetaxel in patients treated with docetaxel.
  • To determine toxicity of docetaxel in patients treated with docetaxel.
  • To assess the quality of life of these patients.
  • To evaluate the health economic impact.

OUTLINE: This is a multicenter study.

Patients are stratified according to stage (locally advanced vs metastatic), site of disease (esophagus vs esophagogastric junction vs stomach), duration of response to prior chemotherapy (no response vs response duration < 3 months vs response duration 3-6 months), and ECOG performance status (0-1 vs 2). Patients are randomized to 1 of 2 treatment arms.

  • Arm I: Patients receive docetaxel IV over 1 hour on day 1 and active symptom control (e.g., analgesics [including opioids], antiemetics, steroids, palliative radiotherapy) daily.
  • Arm II: Patients receive active symptom control as in arm I. Courses repeat every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.

Patients in arm I undergo tissue biopsy collection at baseline and after 3 courses of treatment for biomarker analysis.

Quality of life is assessed by the QLQ-C30 and QLQ-STO22 questionnaires at baseline and at 3, 6, 9, 12, 18, and 24 weeks. Health resource use is assessed by the EQ-5D questionnaire at baseline and then periodically during and after treatment.

After completion of study treatment, patients are followed up every 6 weeks for 1 year and then every 3 months thereafter.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Histologically confirmed adenocarcinoma of the esophagus or stomach, including adenocarcinoma of the esophagogastric junction

    • Advanced disease not amenable to curative treatment
    • Documented progressive disease while receiving or within 6 months of completion of first-line chemotherapy with a platinum- and fluoropyrimidine-based therapy either for advanced disease or as neoadjuvant/perioperative therapy
  • No cerebral or leptomeningeal metastasis


  • ECOG performance status 0-2
  • Life expectancy ≥ 12 weeks
  • Hemoglobin ≥ 10 g/dL
  • WBC ≥ 3.0 x 10^9/L
  • ANC ≥ 1.5 x 10^9/L
  • Platelets ≥ 100 x 10^9/L
  • Creatinine normal OR creatinine clearance ≥ 60 mL/min
  • Total bilirubin normal
  • ALT ≤ 1.5 times upper limit of normal (ULN)
  • Alkaline phosphatase ≤ 5 times ULN
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective barrier contraception during and for 3 months after completion of treatment
  • No clinically significant peripheral neuropathy (grade 2-4)
  • No prior malignancy except for curatively treated basal cell carcinoma of the skin or cervical intraepithelial neoplasia
  • No medical or psychiatric condition that would influence the ability of patients to provide informed consent
  • No other serious or uncontrolled illness that, in the opinion of the investigator, makes it undesirable for the patient to enter the trial


  • See Disease Characteristics
  • No prior chemotherapy with taxanes

    • ≤ 1 prior chemotherapy regimen in advanced setting allowed
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00978549

United Kingdom
Bristol Haematology and Oncology Centre
Bristol, England, United Kingdom, BS2 8ED
Addenbrooke's Hospital
Cambridge, England, United Kingdom, CB2 2QQ
Warwick Medical School Clinical Trials Unit
Coventry, England, United Kingdom, CV4 7AL
St. Luke's Cancer Centre at Royal Surrey County Hospital
Guildford, England, United Kingdom, GU2 7XX
Medical Research Council Clinical Trials Unit
London, England, United Kingdom, NW1 2DA
Royal South Hants Hospital
Southampton, England, United Kingdom, SO14 0YG
Aberdeen Royal Infirmary
Aberdeen, Scotland, United Kingdom, AB25 2ZN
Velindre Cancer Center at Velindre Hospital
Cardiff, Wales, United Kingdom, CF14 2TL
Sponsors and Collaborators
Cambridge University Hospitals NHS Foundation Trust
Principal Investigator: Hugo Ford, MD Cambridge University Hospitals NHS Foundation Trust
  More Information Identifier: NCT00978549     History of Changes
Other Study ID Numbers: CRCA-COUGAR-02
CDR0000649670 ( Registry Identifier: PDQ (Physician Data Query) )
Study First Received: September 16, 2009
Last Updated: August 6, 2013

Keywords provided by National Cancer Institute (NCI):
nausea and vomiting
adenocarcinoma of the esophagus
adenocarcinoma of the stomach
adenocarcinoma of the gastroesophageal junction
recurrent gastric cancer
stage IIIA gastric cancer
stage IIIB gastric cancer
stage IIIC gastric cancer
stage IV gastric cancer
recurrent esophageal cancer
stage IIIA esophageal cancer
stage IIIB esophageal cancer
stage IIIC esophageal cancer
stage IV esophageal cancer

Additional relevant MeSH terms:
Stomach Neoplasms
Esophageal Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Stomach Diseases
Head and Neck Neoplasms
Esophageal Diseases
Signs and Symptoms, Digestive
Signs and Symptoms
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action processed this record on April 21, 2017